Alloy Therapeutics, Inc.

Alloy Therapeutics, Inc. is a biotechnology ecosystem company founded in 2017, headquartered in Waltham, MA, with additional research facilities in Cambridge, UK, Basel, and Athens. Its core mission is to democratize access to cutting-edge drug discovery technologies and empower the global scientific community to collaboratively develop better medicines.

The company provides AI-driven platforms, foundational technologies, and integrated wet and dry lab services for drug discovery and development. Key offerings include the ATX-Gx™ transgenic humanized mouse platform for monoclonal antibody discovery, the ATX-CLC platform for bispecific and multispecific discovery, the ATX-SiD platform for single-domain antibodies, and Keyway™ TCR Discovery Services. Alloy also features the AntiClastic™ nucleic acid medicines/ASO platform. These platforms and services are made available to a broad range of partners, from academic scientists and small biotechs to large pharmaceutical companies.

Led by Founder and CEO Errik Anderson, Alloy Therapeutics recently secured a $40 million Series E financing round in April 2026, valuing the company at $1 billion. In March 2026, the company announced an agreement with AbbVie to develop a new antibody platform. Further expanding its capabilities, Alloy acquired Spannerwerks, a drug development consulting firm, in October 2025. The company emphasizes a collaborative model, reinvesting all revenue into innovation, and has facilitated over 100 licensed therapeutic programs, with 22 progressing to clinical development.